Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 14/20 | 0.56 |
| ▸ | BTK | Q06187 | 6/20 | 0.56 |
| ▸ | ITK | Q08881 | 3/20 | 0.56 |
| ▸ | SYK | P43405 | 2/20 | 0.51 |
| ▸ | BMX | P51813 | 1/20 | 0.49 |
| ▸ | BRD4 | O60885 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13859248 | 0.91 | BTK (0.57) | EGFRBTKITKSYKBMX | |
| SCHEMBL18559566 | 0.87 | EGFR (0.57) | EGFRBTKITKSYKBMX | |
| SCHEMBL16204459 | 0.86 | EGFR (0.56) | EGFRBTKITKSYKBMX | |
| SCHEMBL13861126 | 0.85 | BTK (0.54) | EGFRBTKITKSYKBMX | |
| SCHEMBL18559562 | 0.85 | BTK (0.54) | EGFRBTKITKSYKBMX | |
| SCHEMBL13859334 | 0.84 | EGFR (0.58) | EGFRBTKITKSYKBMX | |
| SCHEMBL13859261 | 0.84 | EGFR (0.59) | EGFRBTKITKBMX | |
| SCHEMBL13859333 | 0.82 | BRD4 (0.44) | EGFRBTKSYKBRD4 | |
| SCHEMBL27956436 | 0.80 | EGFR (0.54) | EGFRBTKITKSYKBMX | |
| SCHEMBL18559733 | 0.79 | EGFR (0.56) | EGFRBTKITKSYKBMX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9580427-B2 | Kinase inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-02-28 | — | — | US | disclosed |
| US-20140323464-A1 | KINASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-10-30 | — | — | US | disclosed |
| EP-2710007-A2 | KINASE INHIBITORS | The Regents of the University of California (US) | 2014-03-26 | — | — | EP | disclosed |
| WO-2012158843-A2 | KINASE INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323464-A1 | KINASE INHIBITORS | MAP3K20, MAP3K19, MAP3K1 | EGFR 432/4885BTK 279/4885ITK 507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.